CluenexVertex Pharmaceuticals Incorporated VRTX
Vertex Pharmaceuticals Incorporated scores excellent on business quality (7.8 of 10). Here is why, in plain words, and what our sealed record shows.
Why it matters
- What Vertex Pharmaceuticals Incorporated does
Vertex Pharmaceuticals sells proprietary cystic fibrosis treatments, collecting premium prices from healthcare payers worldwide. The company is expanding beyond its core franchise into gene therapies and non-opioid pain management.
- What it does best
Vertex dominates cystic fibrosis care, posting an 86.0% gross margin that easily outpaces peers like AbbVie at 72.8%. This monopoly pricing power stems from decades of targeted molecular R&D that rivals cannot easily replicate.
- The main risk
Heavy pipeline concentration in cystic fibrosis creates revenue exposure if upcoming gene therapy launches face unexpected regulatory hurdles or slow commercial uptake.
Quality, check by check
Scored against its own industry, from company filings.
Operating margin hits 39.0% with an FCF margin in the sector's top quartile at 89%, showing elite operating leverage as revenue scales.
Patent protection and deep clinical expertise lock in patients and rare disease specialists, landing gross margins in the top decile of its sector at 89%.
Revenue growth sits at 8.9% annually, supported by the core cystic fibrosis portfolio while newer non-CF programs ramp up.
Net cash of $6.5 billion shields a pristine balance sheet. Free cash flow reached $3.8B, getting stronger as legacy patent revenues compound.
Insiders
Executives and directors, from SEC Form 4 filings we read ourselves. Open market trades only; grants, option exercises and pre-planned sales left out.
No open market buys or unplanned sales by executives or directors.
Our sealed record on VRTX
Verdicts appear here 30 days after we publish them; members see today's. Each one is in the nightly ledger, fingerprinted the night it was made.
The first sealed verdicts appear here on Oct 11, 2026.
Questions
Vertex Pharmaceuticals Incorporated scores excellent on the Cluenex quality check (7.8 of 10), measured against its own industry. Profitability is strong, moat strong, growth steady and financial health strong.
In the last 90 days of SEC Form 4 filings: No open market buys or unplanned sales by executives or directors.
Nov 2, 2026.
See VRTX today
- Today's verdict on VRTX, and why
- Fair value with cautious, base and optimistic cases
- The exact price that would change the verdict
- Which stocks each signal names, the night it fires
Cite this page: Cluenex, “Vertex Pharmaceuticals Incorporated (VRTX)”, https://cluenex.com/stocks/vrtx/, data as of Oct 10, 2026.